• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Ambrx Biopharma Inc.

    3/8/24 1:34:49 PM ET
    $AMAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AMAM alert in real time by email
    S-8 POS 1 d767293ds8pos.htm S-8 POS S-8 POS

    As filed with the Securities and Exchange Commission on March 8, 2024

    Registration No. 333-257264-01

    Registration No. 333-264490-01

    Registration No. 333-271005-01

    Registration No. 333-271966-01

    Registration No. 333-274952

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    Post-Effective Amendment No. 2 to Registration Statement on Form S-8 (No. 333-257264-01)

    Post-Effective Amendment No. 2 to Registration Statement on Form S-8 (No. 333-264490-01)

    Post-Effective Amendment No. 2 to Registration Statement on Form S-8 (No. 333-271005-01)

    Post-Effective Amendment No. 2 to Registration Statement on Form S-8 (No. 333-271966-01)

    Post-Effective Amendment No. 1 to Registration Statement on Form S-8 (No. 333-274952)

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Ambrx Biopharma, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   93-2892120

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    10975 North Torrey Pines Road

    La Jolla, California 92037

    (Address of Principal Executive Offices, Including Zip Code)

    Ambrx Biopharma, Inc. Second Amended and Restated 2016 Equity Incentive Plan

    Ambrx Biopharma, Inc. Amended and Restated 2021 Equity Incentive Plan

    Ambrx Biopharma, Inc. Amended and Restated 2021 Employee Share Purchase Plan

    Share Options Granted as Employment Inducement Awards Outside of a Plan

    Shares Granted as Compensation in Lieu of Cash

    (Full title of the plan)

     

     

    Sonja Nelson

    Chief Financial Officer

    Ambrx Biopharma, Inc.

    10975 North Torrey Pines Road

    La Jolla, California 92037

    (Name and address of agent for service)

    Telephone: (858) 875-2400

    (Telephone number, including area code, of Agent for Service)

     

     

    Copies to:

    Robert I. Townsend, III

    Ting S. Chen

    Jin-Kyu Baek

    Cravath, Swaine & Moore LLP

    Worldwide Plaza

    825 Eighth Avenue

    New York, New York 10019

    (212) 474-1000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging Growth company   ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒

     

     

     


    EXPLANATORY NOTE

    DEREGISTRATION OF SECURITIES

    These Post-Effective Amendments (these “Post-Effective Amendments”) by Ambrx Biopharma, Inc., a Delaware corporation (the “Company”), relate to the following Registration Statements on Form S-8 (each, a “Registration Statement,” and collectively, the “Registration Statements”):

     

      •  

    Registration Statement on Form S-8 (File No. 333-257264), originally filed with the U.S. Securities and Exchange Commission (the “SEC”) by Ambrx Biopharma Cayman, Inc. (formerly Ambrx Biopharma Inc.), a Cayman Islands exempted company (the “Predecessor Registrant”), on June 22, 2021, as amended by Post-Effective Amendment No. 1 to Registration Statement No. 333-257264-01, filed with the SEC by the Company, as the successor registrant to the Predecessor Registrant, on October 12, 2023, registering (i) 4,499,549 shares of common stock, par value $0.0001 per share (“Shares”), of the Company, issuable in connection with the exercise of outstanding options granted under the Second Amended and Restated 2016 Equity Incentive Plan (the “2016 Plan”); (ii) 3,489,723 Shares, reserved for future issuance under the Amended and Restated 2021 Equity Incentive Plan (the “2021 Plan”); and (iii) 428,571 Shares, reserved for future grants under the Amended and Restated 2021 Employee Share Purchase Plan (the “2021 ESPP”).

     

      •  

    Registration Statement on Form S-8 (File No. 333-264490), originally filed with the SEC on April 26, 2022 by the Predecessor Registrant, as amended by Post-Effective Amendment No. 1 to Registration Statement No. 333-264490-01, filed with the SEC by the Company, as the successor registrant to the Predecessor Registrant, on October 12, 2023, registering (i) an additional 1,929,432 Shares issuable in connection with the 2021 Plan and (ii) an additional 385,886 Shares issuable in connection with the 2021 ESPP.

     

      •  

    Registration Statement on Form S-8 (File No. 333-271005), originally filed with the SEC on March 30, 2023 by the Predecessor Registrant, as amended by Post-Effective Amendment No. 1 to Registration Statement No. 333-271005-01, filed with the SEC by the Company, as the successor registrant to the Predecessor Registrant, on October 12, 2023, registering (i) an additional 1,931,823 Shares issuable in connection with the 2021 Plan and (ii) an additional 386,364 Shares issuable in connection with the 2021 ESPP.

     

      •  

    Registration Statement on Form S-8 (File No. 333-271966), originally filed with the SEC on May 16, 2023 by the Predecessor Registrant, as amended by Post-Effective Amendment No. 1 to Registration Statement No. 333-271966-01, filed with the SEC by the Company, as the successor registrant to the Predecessor Registrant, on October 12, 2023, registering (i) 742,857 Shares issuable in connection with the grant of share options to purchase 742,857 Shares as employment inducement awards outside of a plan, and (ii) 15,000 Shares issuable in connection with the election by Daniel J. O’Connor, President and Chief Executive Officer of the Company, to receive, in lieu of cash, a designated percentage of his salary in the form of Shares.

     

      •  

    Registration Statement on Form S-8 (File No. 333-274952), originally filed with the SEC on October 12, 2023 by the Company, registering an additional 371,428 Shares issuable in connection with the grant of share options to purchase 371,428 Shares, which are of the same class of securities and relate to the same employment inducement awards outside of a plan for which Registration Statement on Form S-8 (File No. 333-271966) was originally filed by the Predecessor Registrant with the SEC on May 16, 2023 and subsequently amended by Post-Effective Amendment No. 1 to Registration Statement No. 333-271966-01, filed with the SEC by the Company, as the successor registrant to the Predecessor Registrant.

    These Post-Effective Amendments are being filed in connection with the closing on March 7, 2024 of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of January 5, 2024 (the “Merger Agreement”), by and among Johnson & Johnson, a New Jersey corporation (“Parent”), Charm Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and the Company. On March 7, 2024, pursuant to the Merger Agreement, Merger Sub was merged with and into the Company (the “Merger”), with the Company surviving the Merger and continuing as a wholly owned subsidiary of Parent.


    As a result of the Merger, the Company has terminated all offerings of the Company’s securities pursuant to its existing registration statements under the Securities Act of 1933, as amended (the “Securities Act”), including the Registration Statements. In accordance with undertakings made by the Company in the Registration Statements to remove from registration, by means of a post-effective amendment, any securities that had been registered for issuance that remain unsold at the termination of the offering, the Company hereby removes from registration all such securities of the Company registered pursuant to the Registration Statements that remain unsold and any plan interests that are unissued as of the date hereof. Each Registration Statement is hereby amended, as appropriate, to reflect the deregistration of such securities.


    SIGNATURES

    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of La Jolla, State of California, on March 8, 2024. No other person is required to sign these Post-Effective Amendments to the Registration Statements in reliance upon Rule 478 under the Securities Act.

     

    AMBRX BIOPHARMA, INC.
    By:  

    /s/ Sonja Nelson

    Name:   Sonja Nelson
    Title:   Chief Financial Officer
    Get the next $AMAM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AMAM

    DatePrice TargetRatingAnalyst
    9/25/2023$15.00Mkt Outperform
    JMP Securities
    9/12/2023$26.00Buy
    BTIG Research
    7/31/2023$29.00Outperform
    RBC Capital Mkts
    6/14/2023$26.00Buy
    B. Riley Securities
    6/2/2023$30.00Outperform
    Oppenheimer
    5/19/2023$25.00Overweight
    Cantor Fitzgerald
    4/7/2022$16.00Outperform
    Robert W. Baird
    2/28/2022$6.00Neutral
    Goldman Sachs
    More analyst ratings

    $AMAM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors

      – Industry veteran to serve as independent director, strengthening the board and bringing extensive leadership, executive and governance experience to Cartography as it builds out its oncology platform and pipeline - Cartography Biosciences, Inc., an oncology company advancing a pipeline of antibody therapeutics that more precisely target tumors, today announced the appointment of Troy E. Wilson, Ph.D., J.D., as an independent director. Dr. Wilson, a 25-year veteran of the biopharma industry, is President, CEO and co-founder of Kura Oncology (NASDAQ:KURA) and has served as chairman of its Board of Directors since it was founded in 2014. "We are delighted to have attracted a true industry

      10/29/24 8:00:00 AM ET
      $AMAM
      $KURA
      $RNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Ambrx Shareholders Approve Acquisition by Johnson & Johnson

      SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., ("Ambrx" or the "Company") (NASDAQ:AMAM), today announced that its shareholders approved a proposal to adopt the merger agreement entered into between the Company and Johnson & Johnson at its Special Meeting of Shareholders. As previously announced, under the terms of the transaction, Ambrx shareholders will receive $28.00 per share in cash in connection with the closing of the transaction. Daniel J. O'Connor, Chief Executive Officer of Ambrx, said, "We want to thank our shareholders for their strong support of this transaction. With a steadfast focus on protein engineering innovation and some of the best ADC talent in t

      3/6/24 1:20:00 PM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ambrx Announces Sale to Johnson & Johnson

      SAN DIEGO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., or Ambrx (NASDAQ:AMAM), today announced that it has entered into a definitive agreement pursuant to which Johnson & Johnson will acquire all of the outstanding shares of Ambrx for $28.00 per share in cash, representing an approximately 105% premium to Ambrx's closing stock price on January 5, 2024, for a total equity value of approximately $2.0 billion. "We are excited to reach this agreement with Johnson & Johnson for advancing scientific research to treat cancers with high unmet needs," said Daniel J. O'Connor, Chief Executive Officer of Ambrx. "With our deep and unique knowledge of precision engineering of protein ther

      1/8/24 7:35:00 AM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMAM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Hermans Kate

      4 - Ambrx Biopharma, Inc. (0001990550) (Issuer)

      3/7/24 7:23:35 PM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Loesberg Janet

      4 - Ambrx Biopharma, Inc. (0001990550) (Issuer)

      3/7/24 7:19:43 PM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • O'Connor Daniel J. returned 48,202 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Ambrx Biopharma, Inc. (0001990550) (Issuer)

      3/7/24 5:46:49 PM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMAM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • JMP Securities initiated coverage on Ambrx Biopharma with a new price target

      JMP Securities initiated coverage of Ambrx Biopharma with a rating of Mkt Outperform and set a new price target of $15.00

      9/25/23 7:12:57 AM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BTIG Research initiated coverage on Ambrx Biopharma with a new price target

      BTIG Research initiated coverage of Ambrx Biopharma with a rating of Buy and set a new price target of $26.00

      9/12/23 7:13:06 AM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • RBC Capital Mkts initiated coverage on Ambrx Biopharma with a new price target

      RBC Capital Mkts initiated coverage of Ambrx Biopharma with a rating of Outperform and set a new price target of $29.00

      7/31/23 7:17:15 AM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMAM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Cormorant Asset Management, Lp bought $19,625,601 worth of Ordinary Shares (2,152,738 units at $9.12)

      4 - Ambrx Biopharma Inc. (0001836056) (Issuer)

      9/19/23 4:49:06 PM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMAM
    SEC Filings

    See more
    • SEC Form 15-12G filed by Ambrx Biopharma Inc.

      15-12G - Ambrx Biopharma, Inc. (0001990550) (Filer)

      3/18/24 2:45:48 PM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ambrx Biopharma Inc. filed SEC Form 8-K: Leadership Update

      8-K - Ambrx Biopharma, Inc. (0001990550) (Filer)

      3/12/24 4:55:02 PM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Ambrx Biopharma Inc.

      EFFECT - Ambrx Biopharma, Inc. (0001990550) (Filer)

      3/11/24 12:15:20 AM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care